Anlon Healthcare is expanding beyond its core API business with the acquisition of a majority stake in Remember India Health Links, marking its entry into finished dosage formulations and integrated pharmaceutical operations.
Glimpse:
Announced in April 2026, Anlon Healthcare approved the acquisition of a 63.98% stake in Remember India Health Links for ₹5.38 crore. The deal involves the purchase of 1.11 crore equity shares and is expected to close within 4–5 months. The move enables Anlon to transition from API manufacturing into finished formulations, strengthening its position across the pharmaceutical value chain.
Gujarat based Anlon Healthcare has taken a significant strategic step by approving the acquisition of a 63.98% stake in Remember India Health Links, a pharmaceutical formulations company. The transaction, valued at ₹5.38 crore, is structured as a cash deal and is expected to be completed within four to five months, subject to standard conditions.
The acquisition marks a key shift in Anlon’s business model. Traditionally focused on active pharmaceutical ingredients (APIs), the company is now moving into finished dosage formulations (FDFs), enabling it to participate more directly in end-product markets, regulatory filings, and branded or generic drug segments.
Remember India Health Links, incorporated in 2020, is engaged in the manufacturing of finished pharmaceutical products such as tablets and capsules. The company also brings a portfolio of more than 30 formulation dossiers, providing Anlon with immediate capabilities in product development and commercialization.
Upon completion of the transaction, Remember India Health Links will operate as a subsidiary of Anlon Healthcare, allowing tighter operational and strategic integration. This is expected to enhance quality control processes, streamline manufacturing, and improve overall efficiency across both API and formulation segments.
From a financial and strategic perspective, the acquisition is likely to diversify revenue streams and improve margins by enabling Anlon to move up the value chain. It also positions the company to evolve from a backend ingredient supplier into a more comprehensive pharmaceutical player with presence in both domestic and global markets.
The move aligns with Anlon’s broader inorganic growth strategy, as the company continues to pursue acquisitions to scale its capabilities and compete with more integrated pharmaceutical firms.
“The objective is to transform from an API manufacturer to a complete pharmaceutical provider.”
By
HB Team
Related News
